F&V Capital Management LLC Acquires 2,260 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

F&V Capital Management LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 141,455 shares of the biopharmaceutical company’s stock after purchasing an additional 2,260 shares during the period. Gilead Sciences accounts for 3.1% of F&V Capital Management LLC’s holdings, making the stock its 14th biggest holding. F&V Capital Management LLC’s holdings in Gilead Sciences were worth $10,362,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tompkins Financial Corp lifted its position in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $29,000. Private Wealth Management Group LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $29,000. Sachetta LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $30,000. Finally, Rakuten Securities Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $33,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

GILD stock traded down $0.30 during midday trading on Wednesday, hitting $69.31. 5,794,745 shares of the stock traded hands, compared to its average volume of 7,638,972. The firm has a market cap of $86.35 billion, a P/E ratio of 192.53, a PEG ratio of 2.96 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The stock’s fifty day simple moving average is $65.84 and its 200-day simple moving average is $72.77. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $1.37 earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.44%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of analyst reports. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a research report on Wednesday, April 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Thursday, June 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $74.00 price target on shares of Gilead Sciences in a report on Friday, June 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Finally, Wells Fargo & Company decreased their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $83.47.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.